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Background: Atrial fibrillation is a major risk factor for ischemic stroke. However, the 
prognostic impact of atrial fibrillation among patients with stroke is not fully clarified. We 
compared patient characteristics, including severity of stroke and comorbidity, quality of 
in-hospital care and outcomes in a cohort of first-time ischemic stroke patients with and without 
atrial fibrillation.
Methods: Based on linkage of public medical databases, we did a population-based follow-up 
study among 3,849 stroke patients from the County of Aarhus, Denmark admitted in the period 
of 2003–2007 and prospectively registered in the Danish National Indicator Project.
Results: Atrial fibrillation was associated with an adverse prognostic profile but not with an 
overall poorer quality of in-hospital care. Patients with atrial fibrillation had a longer total length 
of stay (median: 15 vs 9 days), and were at increased risk of in-hospital medical complications 
(adjusted relative risk = 1.48, 95% CI: 1.23–1.79) and recurrent stroke (adjusted hazard 
ratio = 1.30, 95% CI: 0.93–1.82) when compared with patients without atrial fibrillation. The 
adjusted hazard ratios for 30 days and one year mortality were 1.55 (95% CI: 1.20–2.01) and 
1.55 (95% CI: 1.30–1.85), respectively. Patients not eligible to oral anticoagulant treatment had 
an increased risk of recurrent stroke (adjusted hazard ratio = 1.92, 95% CI: 1.19–3.11).
Conclusion:  Atrial fibrillation is associated with a poor outcome among patients with ischemic 
stroke particularly among patients, who are not eligible to oral anticoagulant treatment.
Keywords: atrial fibrillation, stroke, quality of care, prognosis, mortality, epidemiology
Introduction
Atrial fibrillation is the most common cardiac arrhythmia and a major risk factor for 
ischemic stroke,1 in particular among elderly patients.2 Atrial fibrillation is present 
in approximately 1% of the general population, but is mainly found among elderly 
where the prevalence is substantially higher (eg, approximately 9% of people older 
than 80 years).3
Stroke is one of the most feared complications in patients with atrial fibrillation, 
in particular since atrial fibrillation has been reported to be associated with a higher 
short- and long-term case fatality following stroke.4–12
A number of mechanisms have been suggested to explain this increased mortality 
among stroke patients with atrial fibrillation, including a higher stroke severity,4,7,13–15 
higher age,16 more comorbidity17,18 and poorer quality of care.6 However, the impact 
of these individual factors remains to be clarified. Furthermore, more information 
is needed on the prognosis of atrial fibrillation patients, who are not eligible to oral 
anticoagulant therapy.Clinical Epidemiology 2009:1 56
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We therefore examined the prognosis among patients 
with ischemic stroke in a population-based cohort to clarify 
whether atrial fibrillation is an independent prognostic factor 
among patients with ischemic stroke.
Methods
The Danish national indicator Project
The Danish National Health Service provides tax-supported 
health care to the country’s 5.4 million residents, all of 
whom have free access to hospital care. The Danish National 
Indicator Project is a nationwide initiative to monitor and 
improve the quality of care for specific diseases, including 
stroke.19 The project focuses on the development and imple-
mentation of evidence-based indicators of quality of care 
related to the structure, process and outcome of health care. 
Participation in the project is mandatory for all hospital 
departments treating patients with stroke.
The study was approved by The Danish National Indica-
tor Project and the Danish Data Protection Agency (record 
number: 2007-41-0012).
study population
We conducted this cohort study using population-based 
medical databases covering the population of the former 
County of Aarhus (approximately 650,000 people or 12% 
of the entire Danish population).
Our study population (n = 3,849) included patients 
18 years old admitted between Jan 13, 2003–Dec 31, 2007. 
We included patients diagnosed with an acute first-time 
ischemic or unspecific stroke event according to the World 
Health Organization (WHO) criteria (ie, rapidly developing 
clinical symptoms and signs of focal or global loss of cerebral 
function lasting more than 24 hours or until death, with no 
apparent cause other than vascular origin).20
We excluded patients with intracranial hemorrhage, 
subdural hematoma, epidural hemorrhage, retinal infarct, 
and infarct caused by trauma, infection, or an intracranial 
malignant process.
Our study population included 741 patients with atrial 
fibrillation (19%) and 3,108 patients without atrial fibril-
lation (81%). Atrial fibrillation was defined as a history of 
atrial fibrillation and/or atrial fibrillation diagnosed during 
the index admission with stroke. No distinction was made 
between chronic and paroxystic atrial fibrillation.21
Prognostic factors
The following prognostic factors were registered in the 
Danish National Indicator Project: gender, age, civil status 
(alone or living with someone), housing situation (own 
home, nursing home or other institution), pre-admission 
Rankin Scale score, Scandinavian Stroke Scale score, Barthel 
Index score, hypertension, hypercholesterolemia (total 
cholesterol 5 mmol/L and/or low-density lipoprotein [LDL] 
3 mmol/L), smoking habits (current (1 cigarette/day), 
former smoker (6 months), sometimes (1 cigarette/day) 
and never), alcohol intake (14/21 or 14/21 units/week 
for women and men, respectively) and hospital department. 
Further, we computed the Charlson Index of Comorbidity 
for each patient based on data from the National Registry 
of Patients which contains data on all discharges from all 
nonpsychiatric hospitals in Denmark since 1977. The files 
include information on the civil registry number; date of 
admission and discharge; and up to 20 discharges diagno-
ses and procedures coded according to the International 
Classification of Diseases, 8th revision until the end of 1993 
and 10th revision thereafter. The Charlson Index of Comor-
bidity covers 19 conditions, including chronic obstructive 
pulmonary disease, diabetes mellitus, intermittent claudica-
tion, acute myocardial infarction, congestive heart failure, 
carotid stenosis, and cancer, each weighted according to its 
impact on survival.22,23 We defined three levels of comorbidity 
for each patient, based on their complete hospital discharge 
history, as follows: 0 comorbidities (“low”), 1–2 comorbidi-
ties (“moderate” ) and 3 comorbidities (“high”).
Stroke severity was assessed by the Scandinavian Stroke 
Scale score 24 hours of admission (very severe (14), severe 
(15–29), moderate (30–44), and mild (45 pts)). The scale is 
a validated and widely used neurological stroke scale in Scan-
dinavia that evaluates level of consciousness; eye movement; 
power in the arm, hand, and leg; orientation; aphasia; facial 
paresis; and gait on a total score that ranges from 0 to 58.24,25
The patients’ pre-stroke functional ability was assessed 
with the modified Rankin score which scales the patients from 
0 (no symptoms) to 5 (bedridden, incontinent and requiring 
constant nursing care and attention).
During hospitalization the patients’ functional status 
was measured with Barthel Index score on day 7 ± two days 
(low (60) to high (60)). Barthel Index is commonly used 
to score a patient’s self-care performance and consists of 
10 different rated items including bladder and bowel control, 
bathing, and feeding. The score ranges from 0 (inability to 
perform) to 100 (complete independence).26
Quality of care criteria
Quality of in-hospital care was defined as fulfillment of a 
set of quality of care criteria. An expert panel including Clinical Epidemiology 2009:1 57
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physicians, nurses, physiotherapists, and occupational 
therapists defined 14 quality of care criteria covering the 
acute phase of stroke based on a systematic search of the 
scientific literature:19 admission to a specialized stroke unit, 
antiplatelet therapy initiated among patients with ischemic 
stroke without atrial fibrillation, oral anticoagulant therapy 
initiated among patients with ischemic stroke and atrial 
fibrillation, examination with computed tomography (CT) 
or magnetic resonance imaging (MRI) scan, assessment by 
a physiotherapist, assessment by an occupational therapist, 
assessment of nutritional risk, mobilization, screening for 
dysphagia with water swallow test, individual nutritional 
therapy initiated among patients with a nutritional risk 
score 3, use of sterile intermittent catheterization among 
patients with urinary retention, assessment by a logopedic, 
a neuropsychologist and a social worker.
A time frame was defined for each criterion to capture 
the timeliness of the interventions. The time frame was the 
first day of hospitalization for examination with CT/MRI 
scan, mobilization and screening for dysphagia. The time 
frame was second day of hospitalization for admission to a 
specialized stroke unit, antiplatelet therapy, assessment by 
a physiotherapist, assessment by an occupational therapist, 
and assessment of nutritional risk, whereas time frame for 
anticoagulant therapy was the 14th day of hospitalization for 
initiation of oral anticoagulant therapy and before discharge 
for individual nutritional therapy, sterile intermittent catheter-
ization and assessment by a logopedic, a neuropsychologist 
and a social worker.
A specialized stroke unit was defined as a hospital 
department/unit that exclusively or primarily is dedicated 
to patients with stroke and which is characterized by 
multidisciplinary teams, a staff with a specific interest in 
stroke, involvement of relatives and continuous education 
of the staff. Initiation of antiplatelet (acetylsalicylsyre, 
dipyridamol, and clopidogrel) and oral anticoagulant 
(warfarin and phenprocoumon) therapy was defined as 
continuous use of the drugs and not merely a single dose. 
Assessment by a physiotherapist, occupational therapist, 
logopedic, neuropsychologist and social worker was defined 
as a formal in-person assessment of the patient’s needs, 
whereas assessment of nutritional risk was defined as an 
assessment following the recommendations of the European 
Society for Parenteral and Enteral Nutrition, ie, calculation 
of a score which both accounts for the nutritional status and 
for the stress induced by the stroke.27
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Upon hospital admission, data on care, and patient 
characteristics were prospectively collected for each patient 
using a standardized form. After hospital discharge the data 
were entered into a central database. Patients were classified 
as eligible or noneligible for the specific processes of care 
depending on whether the stroke team or physician treating 
the patient identified any contraindications. The specific 
contraindications for the individual patient were not regis-
tered; however, decisions on eligibility or noneligibility for 
treatment made by the staff followed national guidelines for 
stroke treatment as described in the national Danish guidelines 
for treatment of patients with stroke which is comparable to 
international guidelines for stroke treatment.28 Thus, with these 
national guidelines in mind, it was ultimately left to the staff to 
decide whether or not contraindications to the specific criteria 
were present. Guidelines from the Danish Society of Cardiol-
ogy on oral anticoagulant treatment were followed, eg, severe 
dementia, recent major surgery, antiplatelet therapy, uncon-
trolled hypertension, alcoholism, pregnancy (first trimester) 
and lack of acceptance from the patient were contraindications 
in a patient with ischemic stroke and atrial fibrillation.
Clinical outcomes
We assessed the following clinical outcomes:
Medical complications
Included in-hospital urinary retention, pneumonia, urinary 
tract infection, obstipation and other complications (including 
pressure ulcers, trauma from falling, deep venous thrombosis, 
and lung embolism).
Length of hospital stay
Length of stay was defined from the day of admission to a 
hospital department to the day of discharge to either own 
residence, care home or other type of institution. Length of 
stay included both the acute inpatient hospital stay and the 
inpatient rehabilitation stay. Restricting the analyses to the 
acute inpatient hospital stay yielded similar results and thus, 
we present the results only for the total length of stay.
Recurrent stroke
Included  both  ischemic  and  hemorrhagic  strokes. 
To be considered a recurrent stroke, the patients needed to 
be discharged for at least one day before readmission to the 
hospital.
Mortality
Short- (30 days) and long-term (one year) mortality. Data on 
vital status were obtained from the Civil Registration System 
which is a unique personal identification number issued to 
all Danish citizens that allows unambiguous linkage between 
various public registries and contains complete electronic 
follow-up data on civil registry number, name, gender, 
date and place of birth, citizenship, vital status, address and 
emigration for the entire Danish population since 1968. 
A minimum of one month of follow-up was available on all 
patients included in the study.
statistical analyses
We first computed the relative risk (RR) for patients with 
atrial fibrillation meeting the quality of care criteria compared 
with patients without atrial fibrillation. Only the crude RRs 
were computed since the care processes had been considered 
relevant by the staff treating the patients included in these 
analyses.
We then used logistic regression analysis to compute 
odds ratios as an estimate of the RRs of in-hospital medical 
complications, including both specific complications and 
any type of complication. Decubitus, falls, deep venous 
thrombosis and pulmonary embolism were combined into 
one category (“Other”) as there were few events.
Linear regression was used to compare length of stay. 
A natural log (ln) transformation was used to correct for the 
right skewness of length of stay. When reporting the find-
ings of the analyses, we transformed the regression estimates 
back into the original units by exponentiating the estimates 
and thereby obtained the ratios of the geometric means of 
length of stay. The analyses were done both with and without 
inclusion of the patients who died in hospital.
We used the life table technique to compute the absolute 
risk of recurrent stroke, 30 day- and one year mortality and 
Cox’s proportional regression analysis to compute crude and 
adjusted hazard ratios as an estimate of the incidence rate 
ratios of recurrent stroke and mortality. Follow-up started on 
the day of admission to any hospital department/ward and 
ended on the day of readmission with stroke, death, emi-
gration or end of the study period, respectively, whichever 
came first. In the analyses on mortality follow-up ended on 
the day of death, emigration or after 30 days and one year 
respectively.
We adjusted for fulfillment of the quality-of-care criteria 
and the prognostic factors in all regression analyses using a 
two-step approach, where we first adjusted for the propor-
tion of fulfilled quality of care criteria and all prognostic 
factors except Scandinavian Stroke Scale score and Barthel 
Index score followed by adjustment for all factors including 
Scandinavian Stroke Scale score and Barthel Index score. Clinical Epidemiology 2009:1 59
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This approach was used in order to explore to which extent 
the prognostic impact of atrial fibrillation is mediated through 
stroke severity and consequently impaired functional level. In 
cases of missing data on the covariates, a separate category 
for missing data was added to the specific covariate. We 
computed 95% confidence intervals (CI) for all estimates. 
Finally, we stratified all analyses according to the patients’ 
eligibility to oral anticoagulant treatment.
All analyses were performed using STATA (version 9.2; 
StataCorp, College Station, TX, USA).
Results
Table 1 displays the descriptive characteristics of the study 
population. Patients with atrial fibrillation were characterized 
by a higher proportion of women, higher age, increased stroke 
severity, lower functional level and more co-morbidities 
compared to patients without atrial fibrillation. Among 
the patients with atrial fibrillation, a total of 136 patients 
(18.4%) had previously been admitted to the hospital with 
atrial fibrillation.
Quality of care
Table 2 presents the fulfillment of quality of care criteria 
among patients with and without atrial fibrillation. The 
differences in quality of care were in general minor. 
However, patients with atrial fibrillation were less likely to be 
mobilized (RR = 0.90, 95% CI: 0.86–0.94), treated in a stroke 
unit (RR = 0.93, 95% CI: 0.88–0.98), have an assessment 
by a physiotherapist (RR = 0.91, 95% CI: 0.84–0.99), 
a occupational therapist (RR = 0.92, 95% CI: 0.84–0.99), 
an early assessment of nutritional risk (RR = 0.89, 95% 
CI: 0.82–0.97) and evaluation by a neuropsychologist 
(RR = 0.61, 95% CI: 0.38–0.98) when compared to patients 
without atrial fibrillation. In contrast, patients with atrial 
fibrillation were more likely to receive individual nutritional 
therapy (RR = 1.07, 95% CI: 1.03–1.11).
A sub-analysis of quality of care stratified according to 
eligibility to oral anticoagulant treatment among the patients 
with atrial fibrillation showed no substantial differences 
(data not shown).
Medical complications
The absolute risk of any in-hospital medical complication 
was 43.3% for those with atrial fibrillation and 24.4% for 
patients without atrial fibrillation (adjusted RR = 1.48, 95% 
CI: 1.23–1.79) (Table 3). The adjusted RR estimates for the 
individual medical complications ranged from 1.02 (95% 
CI: 0.76–1.36) to 1.66 (95% CI: 1.29–2.13) when comparing 
patients with atrial fibrillation to those without. This pattern 
was independent of eligibility to oral anticoagulant treat-
ment.
Length of hospital stay
Patients with atrial fibrillation had a median length of stay of 
15 days (interquartile range: 6–31) whereas patients without 
atrial fibrillation had a median length of stay of 9 days 
(interquartile range: 4–24). The adjusted relative length of 
stay was 1.32 (95% CI: 1.18–1.46). The results remained 
virtually unchanged when restricting the analyses to include 
only the acute phase defined as the length of stay until the 
date of transfer to a rehabilitation facility which applied for 
16% of our study population (n = 620). Atrial fibrillation 
patient had a median length of acute stay of 11 days (inter-
quartile range: 5–22) and patients with no atrial fibrillation of 
8 days (interquartile range: 3–16). There was no difference 
when restricting the analyses only to patients discharged 
alive whether or not the sub acute rehabilitation phase was 
included (data not shown).
The increased length of stay was both found among atrial 
fibrillation patients eligible to oral anticoagulant treatment 
(adjusted relative length of stay = 1.49, 95% CI: 1.30–1.70) 
and among patients with contraindications against oral anti-
coagulant treatment (adjusted relative length of stay = 1.31, 
95% CI: 1.13–1.52).
Recurrent stroke
The median follow-up time for all patients was 1.8 years 
(interquartile range: 0.6–3.2 years). The cumulative risk of 
recurrent stroke during follow-up was 6.6% and 5.8% among 
patients with and without atrial fibrillation, respectively, 
corresponding to an adjusted hazard ratio of 1.30 (95% 
CI: 0.93–1.82) (Table 4). Further adjustment for Scandina-
vian Stroke Scale and Barthel Index had virtually no effect 
on the hazard ratio. The increased risk of recurrent stroke was 
restricted to atrial fibrillation patients with contraindications 
against oral anticoagulant treatment (adjusted hazard ratio 
1.92, 95% CI: 1.19–3.11).
short and long term mortality
The absolute 30-day mortality risk for patients with atrial 
fibrillation was 14.7% compared with 5.8% for patients 
without atrial fibrillation. Adjusting for differences in qual-
ity of care and patient characteristics resulted in a 30-day 
hazard ratio of 1.55 (95% CI: 1.20–2.01). Further adjustment 
for stroke severity and Barthel Index resulted in an adjusted 
30-day hazard ratio of 1.24 (95% CI: 0.95–1.61) (Table 4).Clinical Epidemiology 2009:1 60
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Table 1 Characteristics of 3,849 patients with ischemic stroke from the County of Aarhus registered in the Danish national indicator 
Project, 2003–2007
Atrial fibrillation (n = 741) No atrial fibrillation (n = 3,108)
Sex
Female 411 (55.5%) 1,390 (44.7 %)
Male 330 (44.5%) 1,718 (55.3 %)
Age
65 89 (12.0%) 1,142 (36.7 %)
65–80 287 (38.7%) 1,288 (41.4 %)
80 365 (49.3%) 678 (21.8 %)
Civil status
Co-habiting 299 (40.4%) 1,764 (56.8 %)
Alone 398 (53.7%) 1,244 (40.0 %)
Other 24 (3.2%) 71 (2.3 %)
Missing 20 (2.7%) 31 (1.0 %)
Type of residence
Own residence 628 (84.8%) 2,847 (91.6%)
Care home 81 (10.9%) 164 (5.3%)
Other 14 (1.9%) 54 (1.7%)
Missing 18 (2.4%) 43 (1.4%)
Modified Rankin scale
(pre-admission)
no/Minor symptoms 427 (57.6%) 2,132 (68.6%)
Modest/Moderate symptoms 153 (20.6%) 471 (15.2%)
Much/Constant help needed 53 (7.2%) 119 (3.8%)
Missing 108 (14.6%) 386 (12.4%)
Scandinavian Stroke Scale
Very severe (0–14 pt) 107 (14.4%) 182 (5.9%)
severe (15–29) 103 (13.9%) 222 (7.1%)
Moderate (30–44) 149 (20.1%) 522 (16.8%)
Mild (46–60) 245 (33.1%) 1,689 (54.3%)
Missing 137 (18.5%) 493 (15.9%)
Bartel Index
Low (60) 296 (39.9%) 700 (22.5%)
high (60) 238 (32.1%) 1,315 (42.3%)
Missing 207 (27.9%) 1,093 (35.2%)
Charlson Comorbidity Index
no comorbidity 251 (33.9%) 1.466 (47.2%)
Moderate comorbidity 323 (43.6%) 1.193 (38.4%)
severe comorbidity 167 (22.5%) 449 (14.4%)
Missing 0 (0%) 0 (0%)
Diabetes mellitus
Yes 108 (14.6%) 413 (13.3%)
no 601 (81.1%) 2,662 (85.7%)
Missing 32 (4.3%) 33 (1.1%)
(Continued)Clinical Epidemiology 2009:1 61
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The absolute one-year mortality risk was 31.7% among 
patients with atrial fibrillation and 13.7% for patients without 
atrial fibrillation and the corresponding adjusted hazard ratio 
was 1.55 (95% CI: 1.30–1.85). The adjusted hazard ratio 
dropped to 1.33 (95% CI: 1.12–1.59) after further adjustment 
for stroke severity and Barthel Index.
Major differences in risk of death were found when 
stratifying the analyses according to patients’ eligibility 
to oral anticoagulant treatment. Thus, patients with atrial 
fibrillation eligible for oral anticoagulant treatment had a 
tendency towards a lower adjusted hazard ratio of 30-day 
(0.91, 95% CI: 0.60–1.40) and one-year mortality (0.74, 
95% CI: 0.48–1.15) compared with patients without atrial 
fibrillation. In contrast, patients with atrial fibrillation not 
eligible for oral anticoagulant treatment had an adjusted 
hazard ratio of 30-day and one-year mortality of 2.24 (95% 
CI: 1.59–3.13) and 1.68 (95% CI: 1.20–2.36), respectively, 
compared to patients without atrial fibrillation.
Discussion
In this population-based cohort study we found atrial 
fibrillation to be associated with an overall poorer outcome 
following ischemic stroke, including increased in-hospital 
medical complications, length of stay, mortality and possibly 
also an increased risk of recurrent stroke. The risk of 
recurrent stroke and mortality differed substantially among 
atrial fibrillation patients according to eligibility for oral 
anticoagulant treatment. The poor prognosis appeared only 
partly to be explained by a more adverse prognostic patient 
profile, including a higher stroke severity, and not by a poorer 
quality of acute hospital care.
Methodological considerations
The main strengths of our study are its large size, the 
uniformly organized health care system facilitating a pro-
spective population-based design, with complete long-term 
follow-up and use of data collected independently of the 
study objectives. Further, our analyses were based on detailed 
clinical data and included information on a wide range of 
prognostic factors.
Our study was based on data collected during routine 
clinical work, which may potentially have affected the data 
accuracy. Still, participation in the Danish National Indica-
tor Project is mandatory for all departments treating patients 
with stroke in Denmark, and extensive efforts are made to 
ensure the validity of the Danish National Indicator Project, 
including regular structured audit and validation of the 
completeness of patient registration against county hospital 
discharge registries. Furthermore, any misclassification of 
data in the Danish National Indicator Project is unlikely to 
depend on atrial fibrillation and would therefore most likely 
result in conservative risk estimates. Although we adjusted 
for quality of care and a wide range of prognostic factors, we 
cannot entirely exclude the possibility that our results may 
still be influenced by residual confounding due to the use of 
crude categories (eg, diabetes mellitus and hypertension) or 
Table 1 (Continued)
Atrial fibrillation (n = 741) No atrial fibrillation (n = 3,108)
Hypertension
Yes 401 (54.1%) 1,593 (51.3%)
no 303 (40.9%) 1,431 (46.0%)
Missing 37 (5.0%) 84 (2.7%)
Hypercholesterolemia
Yes 241 (32.5%) 1,489 (47.9%)
no 364 (49.1%) 1,314 (42.3%)
Missing 136 (18.4%) 305 (9.8%)
Smoking status
smoker 152 (20.5%) 1,287 (41.4%)
Occasional 16 (2.2%) 61 (2.0%)
Former ( 6 months) 182 (24.6%) 648 (20.8%)
never 248 (33.5%) 837 (26.9%)
Missing 143 (19.3%) 275 (8.9%)
Alcohol status
14/21 drinks/week 549 (74.1%) 2,479 (79.8%)
14/21 drinks/week 39 (5.3%) 258 (8.3%)
Missing 153 (20.7%) 371 (11.9%)Clinical Epidemiology 2009:1 62
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unaccounted confounding from factors not included in the 
analyses (eg, mental function).
Scandinavian Stroke Scale and Barthel Index are 
measures which reflect stroke severity and they may as such 
be considered intermediate steps in the association between 
atrial fibrillation and patient outcome. Adjusting for stroke 
severity and Barthel Index are therefore questionable when 
examining the prognostic role of atrial fibrillation although it 
has been done in a number of studies.4,6,7,14,17,29,30 Thus, if stroke 
severity and Barthel Index are adjusted for, the association 
between atrial fibrillation and adverse outcomes is likely to 
be underestimated as demonstrated in our analyses. Finally, 
it should be noticed that some of the studied outcomes 
(eg, medical complications) were quite common. As a 
consequence the rare disease assumption was not fulfilled 
in all analyses and the computed odds ratios to some extent 
overestimated the true RR.
Comparisons with existing studies
The higher stroke severity found in our study confirms find-
ings from other studies4,6,7,13,14 and most likely reflects that 
ischemic stroke in patients with atrial fibrillation is mainly 
caused by cardiogenic embolisms.31 Ischemic stroke of 
cardioembolic origin is in general associated with a higher 
mortality and a worse functional outcome than other subtypes 
of stroke probably due to the underlying pathophysiology (ie, 
sudden occlusion, often of a relatively large vessel).4,7,13,32,33
Previous studies have indicated that inequalities may 
exist in the quality of care offered to patients with stroke, 
in particular elderly and female patients have been reported 
to be less likely to receive adequate treatment and care.34,35 
Differences in quality of care are important to identify as they 
may contribute to potentially avoidable adverse outcomes for 
selected patient groups. Thus, in a previous study we have 
found a strong association between meeting the quality of 
care criteria in the Danish National Indicator Project and 
short-term mortality.36 However, to our knowledge only one 
study has previously compared the quality of care of patients 
with atrial fibrillation versus patients without atrial fibrilla-
tion. In a multinational European multicenter study of 4462 
stroke patients including 803 with atrial fibrillation, Lamassa 
and colleagues have found brain imaging and other diagnostic 
procedures to be used less frequently among patients with 
atrial fibrillation. Moreover, patients with atrial fibrillation 
received a lower number of physiotherapy and occupational 
therapy sessions.6 However, the study had some methodologi-
cal shortcomings as it was based on patients from selected, 
specialized centers, had incomplete follow-up and lacked 
detailed data on diagnosis and care, including timing of 
the diagnostic procedures and other interventions. We only 
Table 2 Fulfilment of quality of care criteria among ischemic stroke patients with and without atrial fibrillation
Quality of care criterion Atrial fibrillation (%) 
(n = 741)
No atrial fibrillation (%) 
(n = 3,108)
RR (95%CI)
Treatment/rehabilitation in stroke unit (days after admission) 509/719 (70.8%) 2,246/2,955 (76.0%) 0.93 (0.88–0.98)
Antiplatelet therapy (2 days after admission) 448/641 (69.9%) 2,176/2,858 (76.1%) 0.93 (0.88–0.98)
Oral anticoagulant therapy (14 days after admission) 266/383 (69.5%) 130/365 (35.6%) 1.82 (1.57–2.12)
CT/MRi scan (1 days after admission) 409/723 (56.6%) 1,672/3,063 (54.6%) 1.04 (0.96–1.11)
Assessment by a physiotherapist (2 days after admission) 336/625 (53.8%) 1,492/2,537 (58.8%) 0.91 (0.84–0.99)
Assessment by an occupational therapy assessment (2 days 
after admission) 
325/630 (51.6 %) 1,458/2,587 (56.4%) 0.92 (0.84–0.99)
nutritional risk evaluation (2 days after admission)  314/592 (53.0%) 1,466/2,463 (59.5%) 0.89 (0.82–0.97)
Dysphagia screening (24 hours) 386/509 (75.8%) 1,650/2,053 (80.4%) 0.94 (0.89–1.00)
individual nutritional therapy when nutritional score  3 247/258 (95.7%) 621/694 (89.5%) 1.07 (1.03–1.11)
Mobilized (24 hours) 472/617 (76.5%) 2,232/2,616 (85.3%) 0.90 (0.86–0.94)
Urinary retention treated with sterile intermittent 
catheterization
89/92 (96.7%) 174/182 (95.6%) 1.01 (0.96–1.06)
Evaluated by a logopedic 263/297 (88.6%) 886/1,033 (85.8%) 1.03 (0.98–1.08)
Evaluated by a neuropsychologist 16/89 (18.0%) 107/364 (29.4%) 0.61 (0.38–0.98)
Evaluated by a social worker 44/90 (48.9%) 244/441 (55.3%) 0.88 (0.70–1.11)
Notes: *Patients with no atrial fibrillation are the reference group; †Because the proportion of patients eligible for the specific care interventions differs, the total amount 
of patients included differed between each criterion.Clinical Epidemiology 2009:1 63
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found modest differences in quality of in-hospital care in 
our study and adjusting for these differences had virtually no 
impact on patient outcomes. This finding strongly indicates 
that inadequate treatment and care in general is not a major 
contributor to the higher mortality among stroke patients 
with atrial fibrillation.
There are few published data on in-hospital medical 
complications among stroke patients with atrial fibrillation. 
However, our finding of an increased risk of in-hospital com-
plications is supported by findings from the Austrian Stroke 
Registry,30 where atrial fibrillation was associated with an 
increased risk of pneumonia and urinary tract infection.
The increased length of stay in our study for patients 
with atrial fibrillation is in accordance with some4,5 but not 
all existing studies.6,37 An increased length of stay among 
patients with atrial fibrillation may be due to the higher risk of 
in-hospital medical complications, which will require further 
treatment and care before the patient can be discharged. It 
was remarkable that the length of stay was longest among 
the atrial fibrillation patients, who were eligible to antico-
agulant treatment. This could possibly reflect a longer and 
more intense rehabilitation period in these patients compared 
with atrial fibrillation patients who were not eligible to 
anticoagulant treatment; however we did not have data to 
clarify this hypothesis.
We did not find atrial fibrillation in general to be a strong 
independent predictor for recurrent stroke. This finding 
is consistent with some other studies10,38–41 but not all.42,43 
The inconsistencies may at least partly be explained by 
differences in adjustment for other prognostic factors and 
in particular differences related to the effective use of oral 
anticoagulant treatment. Thus, in our study, patients that 
were ineligible to oral anticoagulant treatment had a higher 
stroke recurrence rate.
The overall increased short- and long-term mortality 
among patients with atrial fibrillation in our study is 
consistent with a number of other studies.4–11,44 Different 
mechanisms have been suggested to underlie the increased 
mortality, yet no definitive answer has emerged. The higher 
frequency of in-hospital medical complications and the 
higher risk of recurrent stroke among patients not eligible to 
oral anticoagulant treatment found in our study are, however, 
likely to be important contributors.
Conclusion
Atrial fibrillation is associated with a poorer outcome 
following ischemic stroke, including increased in-hospital 
medical complications, length of stay, mortality and possibly 
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Table 4 Risk of recurrent stroke and mortality among ischemic stroke patients with atrial fibrillation compared to patients without 
atrial fibrillation
Atrial fibrillation 
Absolute risk* (%)
No atrial fibrillation 
Absolute risk* (%)
Crude hazard 
ratio (95% CI)
Adjusted hazard 
rate† (95% CI)
Adjusted hazard ratio† incl. stroke 
severity and Barthel Index (95% CI)
Recurrent stroke 49/741 (6.6%) 181/3,106 (5.8%) 1.44 (1.05–1.98) 1.30 (0.93–1.82) 1.31 (0.93–1.84)
short-term mortality 
(30 days)
109/741 (14.7%) 181/3,106 (5.8%) 2.67 (2.12–3.38) 1.55 (1.20–2.01) 1.24 (0.95–1.61)
Long-term mortality 
(1 year)
235/741 (31.7%) 409/3,106 (13.2%) 2.70 (2.30–3.17) 1.55 (1.30–1.85) 1.33 (1.12–1.59)
Notes: *includes only patients with non-missing values; †Adjusted for prognostic factors (gender, age, civil status, type of residence, pre-admission Rankin scale, Charlson 
Comorbidity Index, hypertension, hypercholesterolemia, smoking, alcohol, hospital department, and proportion of fulfilled quality of care criteria).
also an increased risk of recurrent stroke. The prognosis is 
particularly poor among patients where oral anticoagulant 
treatment is contraindicated. This is only partly explained by 
a more adverse prognostic patient profile, including a higher 
stroke severity, and not by a poorer quality of acute hospital 
care. Continued efforts are warranted in order to improve 
the prognosis of stroke patients with atrial fibrillation, in 
particular patients who are not eligible to oral anticoagulant 
treatment.
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